Next report date
Report period
Q2 2024
EPS estimate
—
Revenue estimate
—
1.3NOK
45.60 MNOK
435.39 MNOK
19.57 M
About VISTIN PHARMA ASA
Sector
CEO
Magnus Tolleshaug
Headquarters
Oslo
Website
Employees (FY)
77
Founded
2015
ISIN
NO0010734122
FIGI
BBG00N0NSXY8
Vistin Pharma ASA engages in the manufacture and sale of metformin products. It offers Metformin HCI and Metformin DC. It operates through the following segments: Pharmaceuticals, Energy Trading, and Headquarter and Other. The company was founded on March 6, 2015 and is headquartered in Oslo, Norway.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VISTNO is 22.4 NOK — it has decreased by 0.44% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange VISTIN PHARMA ASA stocks are traded under the ticker VISTNO.
VISTIN PHARMA ASA is going to release the next earnings report on Aug 23, 2024. Keep track of upcoming events with our Earnings Calendar.
VISTNO stock is 0.45% volatile and has beta coefficient of 0.51. Check out the list of the most volatile stocks — is VISTIN PHARMA ASA there?
Yes, you can track VISTIN PHARMA ASA financials in yearly and quarterly reports right on TradingView.
VISTNO net income for the last quarter is 7.66 M NOK, while the quarter before that showed 18.03 M NOK of net income which accounts for −57.55% change. Track more VISTIN PHARMA ASA financial stats to get the full picture.
Today VISTIN PHARMA ASA has the market capitalization of 1.06 B, it has decreased by 2.61% over the last week.
Like other stocks, VISTNO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VISTIN PHARMA ASA stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 77.00 employees. See our rating of the largest employees — is VISTIN PHARMA ASA on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VISTIN PHARMA ASA technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VISTIN PHARMA ASA stock shows the strong sell signal. See more of VISTIN PHARMA ASA technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VISTIN PHARMA ASA EBITDA is 92.24 M NOK, and current EBITDA margin is 19.06%. See more stats in VISTIN PHARMA ASA financial statements.